Experience

Oct. 27, 2017∼: Takada Legal P.C. (Principal)

Oct., 2016∼Oct., 2017: Paul Hastings LLP (Attorney, New York Office)

Oct., 2015∼Oct., 2016: Gibson Dunn & Crutcher LLP (Associate, New York Office)

Feb., 2015∼Oct., 2015: Wilmer Cutler Pickering Hale & Dorr LLP (Associate, New York Office)

Sept. 2012∼Feb., 2015: Paul Hastings LLP (Associate, New York Office)

Oct., 2010∼Aug., 2011: Columbia University (postdoctoral researcher)

Affiliation

American Bar Association
American Intellectual Property Law Association

Education/Qualification

2014: Registered to practice before the United States Patent and Trademark Office
2012: Passed New York State Bar (Registration in 2013)
2012: Graduated from New York University, School of Law
2010: Obtained Ph.D. from Columbia University (Genetics and Development)
2004: Obtained BA in Biology from Amherst College (Kanzo Uchimura Scholarship, phi beta kappa)
2002: Obtained LLB from University of Tokyo

Litigation Matters (including those from previous firms)

Gevo Inc. v. Betamax Advanced Biofuels (Civil Action No. 11-00054) (Counsel for plaintiff in a biotech patent infringement action)

HELSINN Healthcare S.A. v. Dr. Reddy’s Laboratories, Ltd. et al. (Civil Action Nos. 11-05579; 11-03962; 12-02867)(DDel) (Counsel for plaintiff in ANDA litigation)

Sucampo AG et al. v. Anchen Pharmaceuticals, Inc. et al. (Civil Action 14-07114)(DDel) (Counsel for plaintiffs in ANDA litigation)

TEIJIN Limited and TEIJIN Pharma Limited v. Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. et al. (Civil Action 13-01780; 13-01781; 13-01852; 13-01851; 13-01939; 13-02086; 14-00117; 14-00166; 14-00184; 14-00189; 14-00854; 14-01370)(DDel)( (Counsel for plaintiffs in ANDA litigation)

Sumitomo Dainippon Pharma Co., Ltd. et al. v. Invagination Pharmaceuticals, Inc. et al. (Civil Action 15-00281; 15-00280) (DNJ) (Counsel for plaintiffs in ANDA litigation)

GlaxoSmithKline LLC and GlaxoSmithKline Biological S.A. v. Pfizer Inc. (Civil Action No. 15-01283)(DNJ) (Counsel for plaintiffs in biologic patent infringement litigation)

Novartis AG, Novartis Pharmaceuticals Corporation, Mitsubishi Tanabe Pharma Corporation and Mitsui Sugar Co., Ltd. v. Actavis et al. (Civil Action No. 14-1487; Civil Action No. 15-0150; Civil Action No. 15-0151; Civil Action No. 15-975) (DDel) (Counsel for plaintiffs in ANDA litigation)

Novartis AG, Novartis Pharmaceuticals Corporation and Mitsubishi Tanabe Pharma Corporation v. Milan and Torrent Pharmaceuticals Limited (IPR2014-00784 and IPR2015-00518) (Counsel for plaintiffs in an IPR proceeding)

Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, Janssen Research and Development, LLC, and Cilag GMBH International v. Sandoz Inc. and Zydus Pharmaceuticals (USA) Inc. (Civil Action No. 17-05319)(DNJ) (Counsel for plaintiff in ANDA litigation)

Sumitomo Dainippon Pharma Co., Ltd. et al v. Emcure Pharmaceuticals Ltd.; (Civil Action No. 18-02065)(DNJ) （Counsel for plaintiff in ANDA litigation)

Articles and Speaking Engagements

1. Article：“US Litigation: No need to be scared by deposition? ” (Title translated. Original article in Japanse) : July 28, Ichien Yugo

2. Article：“Inter Partes Review Adds Nother Twist to Hatch-Waxman Litigation”: New York Pharma Forum Blog (April 22, 2014)

3. Article： “The First Supreme Court Review of a Biosimilar Case”: New York Pharma Forum Blog (April 10, 2017)